Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants

Summary

Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines. Booster phase: To compare the safety of and production of antibodies by MnCC with and without MMR and to compare the antibody response to that produced by a low dose of plain polysaccharide vaccine as a way of investigating immune memory

Timeline

Start

1997-06

Primary completion

1998-04

Completion

1998-04

Drugs

Indications